	US 12,343,401 B2
	Modular self assembly disassembly (SADA) technologies
Brian H. Santich, New York, NY (US); Mahiuddin Ahmed, New York, NY (US); and Nai-Kong V. Cheung, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed on Jan. 11, 2023, as Appl. No. 18/153,228.
Application 18/153,228 is a division of application No. 16/609,401, granted, now 11,583,588, previously published as PCT/US2018/031235, filed on May 4, 2018.
Claims priority of provisional application 62/502,151, filed on May 5, 2017.
Prior Publication US 2023/0158162 A1, May 25, 2023
Int. Cl. A61K 47/64 (2017.01); A61K 47/54 (2017.01); A61K 51/04 (2006.01); A61K 51/10 (2006.01); C07K 14/47 (2006.01); C07K 14/715 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01)

CPC A61K 47/641 (2017.08) [A61K 47/547 (2017.08); A61K 51/0495 (2013.01); A61K 51/10 (2013.01); A61K 51/1096 (2013.01); C07K 14/4746 (2013.01); C07K 14/7155 (2013.01); C07K 16/3084 (2013.01); C07K 16/44 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/70 (2013.01)]

11 Claims

1. A method of treating or diagnosing cancer in a subject, comprising:

a. providing a composition comprising a conjugate comprising a self-assembly disassembly (SADA) polypeptide having an amino acid sequence that is identical to a human homo-multimerizing polypeptide sequence comprising any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, and 15 and having one or more multimerization dissociation constants (KD); and a bispecific antibody comprising a first scFv that binds a tumor target and a second scFv that binds a DOTA moiety comprising a radioactive payload, wherein (a) the first scFv is operably linked to the second scFv, (b) the second scFv includes a VH-CDR1 sequence comprising DYGVH (SEQ ID NO: 103), a VH-CDR2 sequence comprising VIWSGGGTAYNTALIS (SEQ ID NO: 104), a VH-CDR3 sequence comprising RGSYPYNYFDA (SEQ ID NO: 105), a VL-CDR1 sequence comprising GSSTGAVTASNYAN (SEQ ID NO: 106), a VL-CDR2 sequence comprising GHNNRPP (SEQ ID NO: 107), and a VH-CDR3 sequence comprising ALWYSDHWV (SEQ ID NO: 108); and (c) the second scFv is operably linked to the SADA polypeptide;

b. administering the composition to a subject that is suffering from or susceptible to cancer; and

c. administering a DOTA chelator comprising a radionuclide.